Bempedoic acid

Adenosine Triphosphate-Citrate Lyase Inhibitor — CARDIOVASCULAR SYSTEM

Key facts

Bempedoic acid is an onp drug in the Adenosine Triphosphate-Citrate Lyase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2020. Its mechanism of action is classified as Adenosine Triphosphate-Citrate Lyase Inhibitors. DrugCentral lists 1 molecular target, including ACLY. Recorded indications include Atherosclerotic occlusive disease and Familial hypercholesterolemia - heterozygous.

• Approval status: onp (first approved 2020 by the FDA).
• Drug class: Adenosine Triphosphate-Citrate Lyase Inhibitor.
• Mechanism of action: Adenosine Triphosphate-Citrate Lyase Inhibitors.
• Molecular targets: ACLY (1 listed in DrugCentral).
• Indications: Atherosclerotic occlusive disease and Familial hypercholesterolemia - heterozygous.
• ATC code: C10AX15 (Other lipid modifying agents).
• Molecular formula: C19H36O5; molecular weight 344.49 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Atherosclerotic occlusive disease
• Familial hypercholesterolemia - heterozygous

Mechanism & targets

• Mechanism of action (MoA): Adenosine Triphosphate-Citrate Lyase Inhibitors
• Established pharmacologic class: Adenosine Triphosphate-Citrate Lyase Inhibitor

Molecular targets (1)

Target	Gene	Action	Activity
ATP-citrate synthase	ACLY	inhibitor	Ki 5.69

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2020-04-01	EMA	—	FGK Representative Service GmbH
2020-02-21	FDA	—	ESPERION THERAPS INC

ATC classification

ATC code	Therapeutic hierarchy
C10AX15	CARDIOVASCULAR SYSTEM › LIPID MODIFYING AGENTS › LIPID MODIFYING AGENTS, PLAIN › Other lipid modifying agents
C10BA10	CARDIOVASCULAR SYSTEM › LIPID MODIFYING AGENTS › LIPID MODIFYING AGENTS, COMBINATIONS › Combinations of various lipid modifying agents

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Myalgia	812.4
Blood creatine phosphokinase increased	192.9
Gout	175.0
Blood uric acid increased	141.8
Muscle spasms	134.5
Muscle rupture	117.8
Low density lipoprotein increased	106.7
Arthralgia	90.9
Muscle discomfort	67.2
Tendon rupture	67.2
Pain in extremity	57.2
Dizziness	54.1

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Bempedoic acid is on its molecule page.

• Molecular formula: C₁₉H₃₆O₅
• Molecular weight: 344.49 g/mol
• CAS number: 738606-46-7
• InChIKey: HYHMLYSLQUKXKP-UHFFFAOYSA-N
• PubChem CID: 10472693

CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Bempedoic acid used for?

DrugCentral lists the following indications for Bempedoic acid: Atherosclerotic occlusive disease and Familial hypercholesterolemia - heterozygous.

How does Bempedoic acid work?

Bempedoic acid is classified as Adenosine Triphosphate-Citrate Lyase Inhibitors; its molecular targets in DrugCentral include ACLY (inhibitor).

When was Bempedoic acid first approved?

Bempedoic acid was first approved by the FDA in 2020.

What drug class does Bempedoic acid belong to?

Bempedoic acid is in the Adenosine Triphosphate-Citrate Lyase Inhibitor class.

What is the chemical formula of Bempedoic acid?

Bempedoic acid has the molecular formula C19H36O5 and a molecular weight of 344.49 g/mol.

Sources

• DrugCentral drug card 5382 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL3545313 — compound record and bioactivity
• PubChem CID 10472693 — chemical identifiers
• DrugBank DB11936 — drug record
• FDA UNII 1EJ6Z6Q368 — substance identity
• DailyMed: FDA labels for Bempedoic acid — current prescribing information (label search)
• UniProt P53396 (ACLY) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.